Discontinued Operations - Schedule of discontinued operation in operations statement (Details)	3 Months Ended
	Mar. 31, 2023 USD ($)
Discontinued operation operating expense
Change in fair value of contingent consideration	$ 1,000,000.0
Net loss from discontinued operations, net of tax benefit	(422,136)
Elusys Therapeutics business unit
Discontinued operation operating expense
Research and development	705,093
Selling, general and administrative	346,857
Amortization of intangible assets	363,750
Change in fair value of contingent consideration	(990,500)
Total operating expenses	425,200
Loss from operations	(425,200)
Other income	(3,064)
Total non-operating gain	(3,064)
Net loss from discontinued operations before income taxes	(422,136)
Net loss from discontinued operations, net of tax benefit	$ (422,136)